What is a stock summary page? Click here for an overview.
Business Description
Allogene Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US0197701065
Description
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.22 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.37 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -4 | |||||
| Beneish M-Score | -1.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 2.1 | |||||
| 3-Year FCF Growth Rate | 12.1 | |||||
| 3-Year Book Growth Rate | -32.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -2.61 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 909.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.6 | |||||
| 9-Day RSI | 56.61 | |||||
| 14-Day RSI | 51.06 | |||||
| 3-1 Month Momentum % | -17.53 | |||||
| 6-1 Month Momentum % | -34.43 | |||||
| 12-1 Month Momentum % | -43.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.54 | |||||
| Quick Ratio | 8.54 | |||||
| Cash Ratio | 8.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.2 | |||||
| Shareholder Yield % | -31.22 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1170372.73 | |||||
| Net Margin % | -1170863.64 | |||||
| FCF Margin % | -913609.09 | |||||
| ROE % | -54.24 | |||||
| ROA % | -42.73 | |||||
| ROIC % | -113.75 | |||||
| 3-Year ROIIC % | 23.27 | |||||
| ROC (Joel Greenblatt) % | -176.58 | |||||
| ROCE % | -46.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.78 | |||||
| Price-to-Tangible-Book | 0.78 | |||||
| EV-to-EBIT | -0.53 | |||||
| EV-to-EBITDA | -0.56 | |||||
| EV-to-Revenue | 6335.73 | |||||
| EV-to-Forward-Revenue | 2223.5 | |||||
| EV-to-FCF | -0.69 | |||||
| Price-to-Net-Current-Asset-Value | 1.87 | |||||
| Price-to-Net-Cash | 1.99 | |||||
| Earnings Yield (Greenblatt) % | -188.68 | |||||
| FCF Yield % | -59.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Allogene Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.022 | ||
| EPS (TTM) ($) | -1.33 | ||
| Beta | 1.05 | ||
| 3-Year Sharpe Ratio | -0.63 | ||
| 3-Year Sortino Ratio | -0.86 | ||
| Volatility % | 57.02 | ||
| 14-Day RSI | 51.06 | ||
| 14-Day ATR ($) | 0.147802 | ||
| 20-Day SMA ($) | 1.458 | ||
| 12-1 Month Momentum % | -43.96 | ||
| 52-Week Range ($) | 1.23 - 3.78 | ||
| Shares Outstanding (Mil) | 217.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allogene Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allogene Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Allogene Therapeutics Inc Frequently Asked Questions
What is Allogene Therapeutics Inc(ALLO)'s stock price today?
The current price of ALLO is $1.55. The 52 week high of ALLO is $3.78 and 52 week low is $1.23.
When is next earnings date of Allogene Therapeutics Inc(ALLO)?
The next earnings date of Allogene Therapeutics Inc(ALLO) is 2025-05-13 Est..
Does Allogene Therapeutics Inc(ALLO) pay dividends? If so, how much?
Allogene Therapeutics Inc(ALLO) does not pay dividend.
Guru Commentaries on NAS:ALLO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers